Evidence map›Paper›PMID 39258900›Full record

ArticleThe Journal of asthma : official journal of the Association for the Care of Asthma2025

Asthma innovations from the second International Collaborative Asthma Network (ICAN) forum.

Nizar N Jarjour, Tonya Winders, Ann M Hansen, Praveen Akuthota, Kian Fan Chung, Hannah Durrington, Stephen J Fowler, Benjamin Gaston, Eneida A Mendonca, Salman Siddiqui and 3 more

Abstract readConference Proceedings
In one paragraph

Article in The Journal of asthma : official journal of the Association for the Care of Asthma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nizar N JarjourUniversity of Wisconsin, Madison, WI, USA.
Tonya WindersGlobal Allergy & Airways Patient Platform, Vienna, Austria.
Ann M HansenUniversity of Wisconsin, Madison, WI, USA.
Praveen AkuthotaUniversity of California San Diego, La Jolla, CA, USA.
Kian Fan ChungNational Heart and Lung Institute, Imperial College London, London, UK.
Hannah DurringtonDivision of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, UK.
Stephen J FowlerDivision of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester, UK.
Benjamin GastonIndiana University, Indianapolis, IN, USA.
Eneida A MendoncaIndiana University, Indianapolis, IN, USA.ORCID 0000-0003-4297-9221
Salman SiddiquiNational Heart and Lung Institute, Imperial College London, London, UK.
Samantha WalkerAsthma + Lung UK, London, UK.
Joe ZeinMayo Clinic, Rochester, MN, USA.
Ratko DjukanovicUniversity of Southampton, Southampton, UK.

Funding

Project 3 - Personalized cystic fibrosis treatment strategies with synergistic therapies Identified in vitro.P01HL128192 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN · 2016 to 2020
$12.2M
S-nitrosylation signaling in asthmaP01HL158507 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI LAHM, TIM · 2021 to 2025
$12.0M
The Impact of Biological Sex on Asthma OutcomesR01HL161674 · NHLBI · MAYO CLINIC ARIZONA · PI Joe Zein · 2023 to 2026
$1.5M
First meeting of the international collaborative asthma networkR13HL156425 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI GASTON, BENJAMIN · 2021 to 2021
$10k
NHLBI NIH HHS P01 HL128192NHLBI NIH HHS P01 HL158507NHLBI NIH HHS R01 HL161674NHLBI NIH HHS R13 HL156425
6 · The paper itself

Abstract

Asthma continues to cause morbidity and mortality despite advances in treatment that include biologics targeting Type 2 inflammation. The International Collaborative Asthma Network (ICAN) forum was developed with the primary goal of promoting innovative, collaborative research that focuses on mechanisms and treatment for asthma that does not respond or that responds poorly to currently available treatments. The mission of ICAN is innovation, collaboration, translation, and increasing high quality research. At the second ICAN meeting, presenters covered a broad scope and depth of asthma-related topics in the categories of complex data, novel therapeutics and diagnostics, breath analysis and microbiome, disease mechanisms, systemic effects, and circadian rhythm. Key actionable needs and research topics were identified during the group discussions. The presentations and discussions that occurred at the second ICAN had an immediate impact on asthma research in the form of new collaborations and implementation of new research ideas and techniques. The forum also served to connect early-stage investigators with investigators who are well established, thereby fostering innovation, translation, and collaboration well into the future. A third ICAN meeting is planned for 2025 to further the innovations and collaborations that will translate into novel therapies and diagnostics to improve the lives of patients with asthma.

Indexed as

AsthmaAnti-Asthmatic AgentsBiomedical ResearchHumansInternational CooperationAnti-Asthmatic AgentsAsthmacollaborationinnovationtranslationType 2 inflammation

Identifiers

PMID39258900
PMCPMC11753940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.